Turning Point Therapeutics (TPTX) Receives $47.17 Average Target Price from Brokerages

Shares of Turning Point Therapeutics (NASDAQ:TPTX) have been given a consensus rating of “Buy” by the six research firms that are currently covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokers that have covered the stock in the last year is $47.17.

A number of equities analysts recently commented on the company. Canaccord Genuity assumed coverage on Turning Point Therapeutics in a report on Monday. They issued a “buy” rating and a $48.00 price objective on the stock. Leerink Swann assumed coverage on Turning Point Therapeutics in a report on Monday. They issued an “outperform” rating and a $42.00 price objective on the stock. Svb Leerink assumed coverage on Turning Point Therapeutics in a report on Monday. They issued an “outperform” rating and a $42.00 price objective on the stock. Wells Fargo & Co assumed coverage on Turning Point Therapeutics in a report on Monday. They issued an “outperform” rating and a $53.00 price objective on the stock. Finally, Goldman Sachs Group assumed coverage on Turning Point Therapeutics in a report on Monday. They issued a “buy” rating and a $50.00 price objective on the stock.

In related news, CEO Athena Countouriotis purchased 12,000 shares of the stock in a transaction on Monday, April 22nd. The shares were bought at an average price of $18.00 per share, for a total transaction of $216,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Brian Lee Baker purchased 2,800 shares of the stock in a transaction on Monday, April 22nd. The shares were bought at an average price of $18.00 per share, for a total transaction of $50,400.00. The disclosure for this purchase can be found here. Insiders purchased 774,800 shares of company stock worth $13,946,400 in the last 90 days.

NASDAQ:TPTX opened at $30.26 on Monday. Turning Point Therapeutics has a 52 week low of $24.21 and a 52 week high of $38.00.

Turning Point Therapeutics Company Profile

Turning Point Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.

See Also: The primary rules of Elliott Wave theory

Analyst Recommendations for Turning Point Therapeutics (NASDAQ:TPTX)

Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.